Bone Health and Osteoclast Targeted Therapies in Advanced Prostate Cancer - Matthew Smith

Matthew Smith shares his thoughts on the importance of bone health in the prostate cancer patient population. Osteoporotic or fragility fractures are common due to the age of the patient and long-term androgen deprivation therapy. Fractures have a great impact on patient mortality, mobility, independence, and overall quality of life. Dr. Smith addresses questions regarding bone density measurement, prevention of skeletal-related events, and the proper timeline for initiation of osteoclast targeted therapy.

Biographies:

Matthew R. Smith, MD, Ph.D., Professor of Medicine, Harvard Medical School, Assistant in Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois, USA.


Read the Full Video Transcript